Myso Finance’s mission is to enable users to generate instant yield and execute bespoke, on-chain structured products via a non-custodial protocol. Myso empowers high-net-worth individuals, DAOs, and treasuries to deploy customized covered calls and cash-secured puts across a wide token universe. 

Enzyme, a leading on-chain asset-management protocol, has acquired a majority stake in Myso Finance in a strategic move to integrate options functionality into its product suite. The acquisition enables Enzyme to offer advanced derivatives and structured products, reinforcing its position as a one-stop platform for tokenized funds, asset managers, and digital-native investors. 

Areta acted as the exclusive financial advisor to Enzyme, supporting the company throughout the acquisition process, identifying Myso as a strategic target, and structuring the transaction to align with Enzyme’s long-term vision of building the most comprehensive on-chain asset-management ecosystem.